Cannabinoid – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Mon, 16 Oct 2023 12:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Cannabinoid – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality https://www.cannabisclinicians.org/2023/10/16/a-double-blind-randomized-placebo-controlled-study-of-the-safety-and-effects-of-cbn-with-and-without-cbd-on-sleep-quality/ Mon, 16 Oct 2023 12:00:00 +0000 https://www.cannabisclinicians.org/?p=29444 The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) 20 mg CBN + 20 mg CBD, or (e) 20 mg CBN + 100 mg CBD for seven consecutive nights. Participants were 18–55 years of age who self-rated sleep quality as “very poor” or “poor.” The primary endpoint was sleep quality, while secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset (WASO), overall sleep disturbance, and daytime fatigue

The post A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males https://www.cannabisclinicians.org/2023/09/26/cannabidiol-oil-ingested-as-sublingual-drops-or-within-gelatin-capsules-shows-similar-pharmacokinetic-profiles-in-healthy-males/ Tue, 26 Sep 2023 10:54:40 +0000 https://www.cannabisclinicians.org/?p=29286 Cannabidiol (CBD) is a nonintoxicating phytocannabinoid used in clinical treatments and sold widely in consumer products. CBD products may be designed for sublingual or oral delivery, but it is unclear whether either is advantageous for CBD absorption. This study compared CBD pharmacokinetics after providing CBD oil as sublingual drops and within orally ingested gelatin capsules, at a dose relevant to consumer products.

The post Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males appeared first on Society of Cannabis Clinicians.

]]> A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral D8-Tetrahydrocannabivarin in Healthy Participants https://www.cannabisclinicians.org/2023/09/22/a-two-phase-dose-ranging-placebo-controlled-study-of-the-safety-and-preliminary-test-of-acute-effects-of-oral-d8-tetrahydrocannabivarin-in-healthy-participants/ Fri, 22 Sep 2023 11:37:48 +0000 https://www.cannabisclinicians.org/?p=29260 Tetrahydrocannabivarin (THCV) is an understudied cannabinoid that appears to have effects that vary as a function of dose. No human study has evaluated the safety and nature of effects in a wide range of THCV doses. This was a two-phase, dose-ranging, placebo-controlled trial of the D8 isomer of oral THCV in healthy adults. Phase 1 utilized an unblinded, single-ascending dose design (n = 3). Phase 2 used a double-blind, random- ized, within-participant crossover design (n = 18). Participants received single acute doses of placebo and 12.5, 25, 50, 100, and 200 mg of THCV. Safety measures and subjective and cognitive effects were assessed predose and up to 8 h postdose.

The post A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral D8-Tetrahydrocannabivarin in Healthy Participants appeared first on Society of Cannabis Clinicians.

]]> THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid https://www.cannabisclinicians.org/2023/07/22/thc-o-acetate-scarce-evidence-for-a-psychedelic-cannabinoid-2/ Sat, 22 Jul 2023 16:01:27 +0000 https://www.cannabisclinicians.org/?p=28963 There is a growing interest in semi-synthetic cannabinoids, including THC-O-acetate (THC-Oac). Some cannabis marketers and users have claimed that THC-Oac produces psychedelic effects; the current study is the first to examine this claim. Researchers developed an online survey for THC-Oac consumers based on previous cannabis and psychedelic use surveys and in consultation with the moderator of an online forum. The survey assessed the experiential profile of THC-Oac and included items from the Mystical Experience Questionnaire (MEQ), an instrument for assessing psychedelic experiences. Participants reported a low to moderate level of cognitive distortions (altered sense of time, difficulties concentrating, difficulties with short-term memory) and few visuals or hallucinations. Participants’ responses were significantly below the threshold for a complete mystical experience on all four MEQ dimensions. Participants who had used classic (5-HT2A agonist) psychedelics had lower scores on all MEQ dimensions. When asked directly, 79% responded that using THC-Oac is “not at all” or “a little” of a psychedelic experience. Some reports of psychedelic experiences may be due to expectations or contaminants. Those having prior experience with classic psychedelics had lower ratings of mystical experiences.

The post THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid appeared first on Society of Cannabis Clinicians.

]]> The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature https://www.cannabisclinicians.org/2023/03/18/the-use-of-cannabinoids-in-the-treatment-of-inflammatory-bowel-disease-ibd-a-review-of-the-literature/ Sat, 18 Mar 2023 14:47:06 +0000 https://www.cannabisclinicians.org/?p=28094 Around the world, about 15 to 40% of individuals with inflammatory bowel disease (IBD) rely on cannabis and cannabinoids to reduce the need for other medications, as well as increase appetite and reduce pain. Whereas more and more patients continue to report benefits accruing from cannabis and cannabinoid usage in IBD, agreement relative to the use of cannabis and its derivatives in IBD remains unclear. This paper reviewed the interplay between cannabinoid use and IBD disease treatment, remission, or symptom relief. The study was conducted from a systematic review perspective. It involved consulting literature from published original research articles, noting outcomes, and performing a meta-analysis to identify trends and draw conclusions. The selected articles were those that had been published in a 10-year period ranging between 2012 and 2022. The motivation was to ensure recency and also relevance to contemporary scientific research and clinical environment practices.

The post The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature appeared first on Society of Cannabis Clinicians.

]]> Cannabis and cannabinoid medications for the treatment of chronic orofacial pain: A scoping review https://www.cannabisclinicians.org/2023/01/21/cannabis-and-cannabinoid-medications-for-the-treatment-of-chronic-orofacial-pain-a-scoping-review-2/ Sun, 22 Jan 2023 00:51:21 +0000 https://www.cannabisclinicians.org/?p=27556 To collate and summarize existing evidence for the use of cannabis and cannabinoids to treat chronic orofacial pain (COP) by oral and maxillofacial surgeons (OMFS), oral medicine specialists (OMS), and orofacial pain specialists (OPS). We systematically screened for sources including a measure of effect of a cannabinoid compound on pain in COP patients that might be treated by our target specialists. Sources were selected by two authors independently. Sources were summarized by country, publication date, objective(s), COP condition(s) studied, cannabinoid(s) studied, methods, results, limitations, and conclusions. A thematic analysis and word cloud were conducted to elucidate commonalities, emphases, and gaps amongst identified sources.

The post Cannabis and cannabinoid medications for the treatment of chronic orofacial pain: A scoping review appeared first on Society of Cannabis Clinicians.

]]> Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment https://www.cannabisclinicians.org/2023/01/13/role-of-the-endocannabinoid-system-in-fragile-x-syndrome-potential-mechanisms-for-benefit-from-cannabidiol-treatment/ Fri, 13 Jan 2023 23:07:18 +0000 https://www.cannabisclinicians.org/?p=27462 Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS). This review describes the ECS, its role in the central nervous system, how it is dysregulated in FXS, and the potential role of cannabidiol as a treatment for FXS. FXS is caused by deficiency or absence of the fragile X messenger ribonucleoprotein 1 (FMR1) protein, FMRP, typically due to the presence of >200 cytosine, guanine, guanine sequence repeats leading to methylation of the FMR1 gene promoter.

The post Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment appeared first on Society of Cannabis Clinicians.

]]> Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review https://www.cannabisclinicians.org/2023/01/13/cannabis-and-cannabinoid-medications-for-the-treatment-of-chronic-orofacial-pain-a-scoping-review/ Fri, 13 Jan 2023 22:50:31 +0000 https://www.cannabisclinicians.org/?p=27459 We systematically screened for sources including a measure of effect of a cannabinoid compound on pain in COP patients that might be treated by our target specialists. Sources were selected by two authors independently. Sources were summarized by country, publication date, objective(s), COP condition(s) studied, cannabinoid(s) studied, methods, results, limitations, and conclusions. A thematic analysis and word cloud were conducted to elucidate commonalities, emphases, and gaps amongst identified sources.

The post Cannabis and Cannabinoid Medications for the Treatment of Chronic Orofacial Pain: A Scoping Review appeared first on Society of Cannabis Clinicians.

]]> Proapoptotic RECS1: a requisite gateway to lysosomal dysfunction and death https://www.cannabisclinicians.org/2022/10/07/proapoptotic-recs1-a-requisite-gateway-to-lysosomal-dysfunction-and-death/ Sat, 08 Oct 2022 01:49:24 +0000 https://www.cannabisclinicians.org/?p=26883 For a long time since their discovery by Christian de Duve in the 1950s, lysosomes have been referred to almost exclusively as passive garbage bags; the endpoint in the degradation of intra- and extracellular cargo. The catabolic function of lysosomes is accomplished by an array of more than 60 acid hydrolases, which together break down a wide variety of biological macromolecules, including proteins, lipids, carbohydrates, and nucleic acids, for reutilization in the metabolic processes of the cell. For their optimal function, these enzymes require an acidic intraluminal pH of ~4.5, which is maintained by the joint action of a proton pump, the vacuolar H+-ATPase, and several ion channels embedded in the lysosomal limiting membrane. Nowadays, lysosomes are envisioned as complex signaling hubs, integrating diverse stimuli about the cell’s metabolic status to coordinate different adaptive responses (Ballabio and Bonifacino, 2020). The lysosome can also induce cell death signals in response to certain conditions, such as infections and treatment with lysosomotropic drugs, which leads to lysosomal membrane permeabilization (LMP) and the release of cathepsins, resulting in lysosomal-mediated cell death.

The post Proapoptotic RECS1: a requisite gateway to lysosomal dysfunction and death appeared first on Society of Cannabis Clinicians.

]]> Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors https://www.cannabisclinicians.org/2022/10/07/cannabinol-inhibits-oxytosis-ferroptosis-by-directly-targeting-mitochondria-independently-of-cannabinoid-receptors/ Sat, 08 Oct 2022 01:33:40 +0000 https://www.cannabisclinicians.org/?p=26878 The oxytosis/ferroptosis regulated cell death pathway recapitulates many features of mitochondrial dysfunction associated with the aging brain and has emerged as a potential key mediator of neurodegeneration. It has thus been proposed that the oxytosis/ferroptosis pathway can be
used to identify novel drug candidates for the treatment of age-associated neurodegenerative diseases that act by preserving mitochondrial function. Previously, we identified cannabinol (CBN) as a potent neuroprotector. Here, we demonstrate that not only does CBN protect nerve cells from oxytosis/ferroptosis in a manner that is dependent on mitochondria and it does so independently of cannabinoid receptors

The post Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors appeared first on Society of Cannabis Clinicians.

]]>